FMP
Advaxis, Inc.
ADXS
PNK
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
0.0333 USD
-0.00085 (-2.55%)
Operating Data
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue
2.33M
253k
3.24M
250k
13k
7.27k
4.07k
2.28k
1.27k
712.06
Revenue %
-
-89.16
1.18k
-92.28
-94.8
-44.06
-44.06
-44.06
-44.06
Ebitda
-17.56M
-24.39M
-18.77M
-15.78M
-35.87M
-7.27k
-4.07k
-2.28k
-1.27k
-712.06
Ebitda %
-752.4
-9.64k
-579.2
-6.31k
-275.92k
-100
-100
-100
-100
Ebit
-19.04M
-26.37M
-19.76M
-16.09M
-36.24M
-7.27k
-4.07k
-2.28k
-1.27k
-712.06
Ebit %
-815.94
-10.42k
-609.75
-6.44k
-278.75k
-100
-100
-100
-100
Depreciation
1.48M
1.98M
990k
314k
369k
5.73k
3.21k
1.79k
1k
561.24
Depreciation %
63.54
781.82
30.56
125.6
2.84k
78.82
78.82
78.82
78.82
Balance Sheet
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Total Cash
16.73M
25.18M
41.61M
25.21M
4.88M
7.27k
4.07k
2.28k
1.27k
712.06
Total Cash %
716.58
9.95k
1.28k
10.08k
37.55k
100
100
100
100
Receivables
469k
469k
681k
234k
-
3.41k
1.91k
1.07k
597.54
334.26
Receivables %
20.09
185.38
21.02
93.6
-
46.94
46.94
46.94
46.94
Inventories
83k
1.34M
-681k
-234k
-
-160.89
-90
-50.35
-28.16
-15.75
Inventories %
3.56
529.25
-21.02
-93.6
-
-2.21
-2.21
-2.21
-2.21
Payable
2.92M
1.08M
2.25M
22k
6.08M
5.5k
3.08k
1.72k
963.34
538.89
Payable %
125.19
427.27
69.6
8.8
46.74k
75.68
75.68
75.68
75.68
Cap Ex
-1.33M
-748k
-460k
-201k
-
-3.66k
-2.05k
-1.14k
-640.49
-358.28
Cap Ex %
-56.98
-295.65
-14.2
-80.4
-
-50.32
-50.32
-50.32
-50.32
Weighted Average Cost Of Capital
Price
0.03
Beta
Diluted Shares Outstanding
6.02M
Costof Debt
189.35
Tax Rate
After Tax Cost Of Debt
175.1
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
8.32M
Total Equity
200.43k
Total Capital
8.52M
Debt Weighting
97.65
Equity Weighting
2.35
Wacc
182.34
Build Up Free Cash Flow
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue
2.33M
253k
3.24M
250k
13k
7.27k
4.07k
2.28k
1.27k
712.06
Ebitda
-17.56M
-24.39M
-18.77M
-15.78M
-35.87M
-7.27k
-4.07k
-2.28k
-1.27k
-712.06
Ebit
-19.04M
-26.37M
-19.76M
-16.09M
-36.24M
-7.27k
-4.07k
-2.28k
-1.27k
-712.06
Tax Rate
7.53
7.53
7.53
7.53
7.53
7.53
7.53
7.53
7.53
7.53
Ebiat
-19.38M
-26.42M
-19.81M
-16.15M
-33.51M
-7.16k
-4.01k
-2.24k
-1.25k
-701.34
Depreciation
1.48M
1.98M
990k
314k
369k
5.73k
3.21k
1.79k
1k
561.24
Receivables
469k
469k
681k
234k
-
3.41k
1.91k
1.07k
597.54
334.26
Inventories
83k
1.34M
-681k
-234k
-
-160.89
-90
-50.35
-28.16
-15.75
Payable
2.92M
1.08M
2.25M
22k
6.08M
5.5k
3.08k
1.72k
963.34
538.89
Cap Ex
-1.33M
-748k
-460k
-201k
-
-3.66k
-2.05k
-1.14k
-640.49
-358.28
Ufcf
-16.85M
-28.29M
-16.3M
-18.27M
-27.09M
-6.08M
-3.84k
-2.15k
-1.2k
-671.96
Wacc
182.34
182.34
182.34
182.34
182.34
Pv Ufcf
-2.15M
-481.57
-95.41
-18.9
-3.75
Sum Pv Ufcf
-2.15M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
182.34
Free Cash Flow T1
-685.4
Terminal Value
-380.06
Present Terminal Value
-2.12
Intrinsic Value
Enterprise Value
-2.15M
Net Debt
3.43M
Equity Value
-5.59M
Diluted Shares Outstanding
6.02M
Equity Value Per Share
-0.93
Projected DCF
-0.92832 1.036%
